First-in-Human Study of Mutant-Selective PI3Ka Inhibitor RLY- 2608 as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Go Back to All Clinical Trials

First-in-Human Study of Mutant-Selective PI3Ka Inhibitor RLY- 2608 as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Brief description of study

Clinical Study Identifier: s24-00014

ClinicalTrials.gov Identifier: NCT05216432

Principal Investigator: Nancy Chan.

Other Investigators: David R. Wise, Elaine Shum, Yoke Wah Khoo, Kirby Rodriguez, Janice Mehnert, Maya Dimitrova, Mariam M Cheaib, Jessica Wang, Joshua K Sabari, Keriann M Scavone, Rajwanth Veluswamy, Eneil De La Pena, Maria Francis, Douglas K Marks, Salman Rafi Punekar, Michelle Diane Swanson Lightfoot, Samantha VanMaanen, Kristen Spencer, Kathleen M Madden, Bhavana Pothuri, Matthew A. Ingham, Kathleen M Lutz.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies